Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Voss

Showing results (231-240 of 419) with videos related to

Pageof 42
Sort By:
Bone Marrow Transplantation|December 6, 2011
Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantationS Avery, M H Voss, A M Gonzales, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Cancer|September 8, 2011
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaAna M Molina, Darren R Feldman, Martin H Voss, et al.
Nature Immunology|September 29, 2001
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transferT Stanislawski, R H Voss, C Lotz, et al.
Pharmacological Research|September 10, 2021
Unraveling binding mechanism and kinetics of macrocyclic Gα<sub>q</sub> protein inhibitorsJan H Voss, Jessica Nagel, Muhammad Rafehi, et al.
The Lancet. Infectious Diseases|June 29, 2019
New hope for tuberculosis vaccinesOle F Olesen, Fareed Abdullah, Rene Coppens, et al.
Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2016
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinomaR Nadal, A Amin, D M Geynisman, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
BMC Urology|July 4, 2020
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinationsYasser Ged, Ruby Gupta, Cihan Duzgol, et al.
Pageof 42

Showing results (231-240 of 419) with videos related to

Sort By:
Pageof 42
Bone Marrow Transplantation|December 6, 2011
Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantationS Avery, M H Voss, A M Gonzales, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Cancer|September 8, 2011
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaAna M Molina, Darren R Feldman, Martin H Voss, et al.
Nature Immunology|September 29, 2001
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transferT Stanislawski, R H Voss, C Lotz, et al.
Pharmacological Research|September 10, 2021
Unraveling binding mechanism and kinetics of macrocyclic Gα<sub>q</sub> protein inhibitorsJan H Voss, Jessica Nagel, Muhammad Rafehi, et al.
The Lancet. Infectious Diseases|June 29, 2019
New hope for tuberculosis vaccinesOle F Olesen, Fareed Abdullah, Rene Coppens, et al.
Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2016
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinomaR Nadal, A Amin, D M Geynisman, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial CarcinomaWassim Abida, Matthew I Milowsky, Irina Ostrovnaya, et al.
BMC Urology|July 4, 2020
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinationsYasser Ged, Ruby Gupta, Cihan Duzgol, et al.
Pageof 42